[HTML][HTML] Individual management of cervical cancer in pregnancy

T Hecking, A Abramian, C Domröse, T Engeln… - Archives of gynecology …, 2016 - Springer
Purpose The management of cervical cancer in pregnancy persists to be challenging.
Therefore, identification of factors that influence the choice of therapeutic management is …

[HTML][HTML] Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group

A Du Bois, N Ewald-Riegler, N De Gregorio… - European journal of …, 2013 - Elsevier
BACKGROUND: Borderline ovarian tumours (BOTs) are recognised as a unique entity of
ovarian tumours that do not exert infiltrative destructive growth or stromal invasion …

Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma

M Pölcher, M Braun, N Friedrichs, C Rudlowski… - Cancer immunology …, 2010 - Springer
Preoperative neoadjuvant chemotherapy (NAC) can significantly reduce tumour burden in
patients with primarily unresectable chemosensitive tumours, allowing a more complete …

Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma

K Kübler, TH Ayub, SK Weber, O Zivanovic… - Gynecologic …, 2014 - Elsevier
Objective Endometrial adenocarcinoma is one of the most common gynecologic
malignancies worldwide and in stages confined to the uterus considered to have an …

HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum …

O Zivanovic, A Abramian, M Kullmann… - … Journal of Cancer, 2015 - Wiley Online Library
This phase I study tested the safety, feasibility, pharmacokinetics and pharmacodynamics of
cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion …

[HTML][HTML] Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the …

F Trillsch, S Mahner, L Woelber, E Vettorazzi, A Reuss… - Annals of oncology, 2014 - Elsevier
Background Approximately one-third of all borderline ovarian tumours (BOT) are diagnosed
in patients with child-bearing potential. Detailed information regarding their specific …

[HTML][HTML] Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer

TH Ayub, MD Keyver-Paik, M Debald, B Rostamzadeh… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured.
One of the major reasons lies in the presence of drug-resistant cancer stem-like cells …

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy

Y Tolkach, H Gevensleben, R Bundschuh… - Breast cancer research …, 2018 - Springer
Purpose Prostate-specific membrane antigen (PSMA), a protein product of the folate
hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron …

Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer

M Debald, A Abramian, L Nemes, M Döbler… - Breast cancer research …, 2015 - Springer
Several authors question the potential benefit of preoperative magnetic resonance imaging
(MRI) against the background of possible overdiagnosis, false-positive findings, and …

[HTML][HTML] Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology

T Hecking, T Thiesler, C Schiller, JM Lunkenheimer… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Vulvar cancer is rare but incidence rates are increasing due to an aging population and
higher frequencies of young women being affected. In locally advanced, metastatic or …